(NewsUSA) – Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia. Last year, the American Cancer Society estimated that nearly 16,000 Americans were diagnosed with this disease.

Jason Whiting, Sr. never imagined he would be one of them.

Several years ago, 36 year-old Jason, a Baltimore-based father of two, visited his doctor to see why the lymph nodes in his neck were enlarged. He was immediately referred to Dr. Stephen Noga, director, medical oncology/hematology at Alvin & Lois Lapidus Cancer Institute, who completed blood and bone marrow tests, which confirmed that Jason had CLL. with the diagnosis came mixed emotions — fear, shock and relief that it was detected early.

Given the early-stage diagnosis, Jason experienced minimal symptoms, and he and Dr. Noga decided to initially take a “watch and wait” approach to treatment — a common practice for CLL patients. Over the next several years, Jason had blood tests and CAT scans to monitor his disease progression.

In may 2009, Jason experienced discomfort in his chin and neck, and a CAT scan showed that the cancer had spread to lymph nodes in his abdomen and chest. both Jason and Dr. Noga agreed — it was now time to begin treatment and the fight against cancer.

“It was important that Jason be comfortable with his treatment approach, and we spent a lot of time discussing options,” said Dr. Noga.

Dr. Noga prescribed TREANDA, and after six cycles of TREANDA, Jason has achieved partial remission.

Jason didn’t fight this battle alone. Throughout his treatment, Jason relied on the support of his family and his coworkers.

“When I was diagnosed, I made a decision to beat CLL,” said Jason. “I knew I had to stay positive and motivated so the cancer would not get the best of me. I am thankful for everyone who supported me through the experience.”

Grateful to have achieved partial remission, Jason can be found practicing martial arts and spending time with his children — something that he never takes for granted.

Individual results may vary.

• Copyright 2012, Internet Broadcasting. this material may not be published, broadcast, rewritten or redistributed.

Cerebroad Cinnarizine 25mg 250Tablets Cerebral arterio sclerosis symptoms MigrainePackage : 25×10 tablets.(250 tablets)Cinnarizine 25 mg is used for treatment of Labyrinthopaty, vascular vestibulopathy, Meniere?€?s disease; prevention and treatment of kinesis.Cinnarizine 25 mg Dosage and administration: – Cinnarizine 25 mg is used orally, before nutrition. In prevention of kinesis – 25 mg, a half to one hour before the traveling, and after that – 25 mg each 6 hours. For the treatment of patients with labyrinthopaty, vestibular disorders,and Meniere?€?s disease the dose is 75 mg, given three times daily. Maximal dose in adults is 225 mg/24 h. In order to achieve an optimal therapeutic effect Cinnarizine 25 mg should be used for several months.In elderly patients the treatment should be started with low doses (average ?? of the recommended dose), with gradually increase of the daily dose until the expected therapeutic effect is achieved.In children recommended daily dose is average of the daily dose in adults.Contraindications of Cinnarizine 25 mg : Hypersensitivity to the preparation; pregnancy and lactation.Cinnarizine 25 mg Special warnings and precautions: Cinnarizine 25 mg should be used with care in: adult patients, children, patients with family history or clinical manifestations of extrapyramidal disorders. In persons with hypotension during the treatment the blood pressure shouldbe monitored. In long-term treatment with Cinnarizin hematology variables, iver and renal laboratory tests should be monitored. Cinnarizine 25 mg may cause a somnolence, which reduces the attention and disturbs the driving capabilities,particularly in the beginning of the treatment. This requires special care when using the medicine in drivers and machinery operating persons.Cinnarizine 25 mg Drug interactions: Cinnarizine 25 mg may potentiate the effects of the antidepressants and alcohol.Antiacide medicines and H2-blockers accelerate the resorption of the preparation, reducing acidity of the stomach fluid.Nootrope agents and vasodilators increase Cinnarizine 25 mg effects.Cinnarizine 25 mg Adverse reactions: at the onset of the treatment the most frequent adverse reactions are:somnolence, abdominal pain and discomfort, which usually are transitory and resolve after the dose adjustment.Hypersensitivity reactions usually affect the skin. Cinnarizine 25 mg may intensify the trend to hypotension reactions orpreexistent hypotension, xerostomia, appetite increase. The most serious adverse reactions are extrapyramidal disorders (tremor, disorientation, balance disorders), including Parkinson?€?s syndrome. Cinnarizine 25 mg may cause false doping-positivereactions in sportsmen. due to its antihistamine effect Cinnarizin may lead to false – negative result in intradermal hypersensitivity testing. In this reason the treatment with Cinnarizine 25 mg should be discontinued at least 4 days before the testing.Pharmacological mechanisms: Cinnarizine 25 mg improves the brain and peripheral microcirculation, antagonizing vascular effects of the endogenous monoamines and oligopeptides, and blocking the calcium influx in the myocytes of the vessel wall. Cinnarizine 25 mg possesses a high affinity to the vessel smooth muscle cells in the brain. Cinnarizine 25 mg reduces the erythrocyte deformity and improves rheology of the blood. Improves the cell resistance to hypoxia. Cinnarizin has no cardiodepressive effect. Reduces nystagmus and other vestibular disorders, reduces the labyrinth irritability. Exerts certain antihystamine action.Generic name: Cinnarizine 25 mg

Patients with osteoporosis, or brittle bone disease, are often given drugs to strength their bones and slow down the thinning.

These drugs can also be given to cancer patients who are suffering with bone loss symptoms such as those with multiple myeloma, where cells in the bone marrow destroy bone leaving it weakened.

The largest and most comprehensive study yet, conducted by British researchers, has now found that one of the drugs, called zoledronic acid, improves survival in those cancer patients as well as preventing bone loss.

The findings were published in the Lancet medical journal and presented at the American Society of Hematology meeting in Orlando, Florida.

Professor Gareth Morgan, of the Institute of Cancer Research, London, UK, and Professors Walter Gregory and Anthony Child, of Clinical Trials Research Unit at University of Leeds compared zoledronic acid against a similar drug, clodronic acid in a group of almost 2,000 patients.

It was found that zoledronic acid reduced mortality by 16 per cent and extended overall survival by 5·5 months from 44.5 months to 50 months when compared with clodronic acid.

The authors wrote in the Lancet: “the improvement in overall survival with zoledronic acid remained significant after adjustment for the reduction in risk of skeletal-related events. These data add to growing clinical evidence supporting anticancer benefits with zoledronic acid in patients with newly diagnosed cancers

“Although we have not definitively identified the underlying mechanism of action, the early improvement in overall survival with zoledronic acid compared with clodronic acid supports early use of zoledronic acid in multiple myeloma.”

In an accompanying comment article, Dr Vincent Rajkumar, of the Mayo Clinic in Rochester, Minnesota, said other less expensive drugs are available which have fewer side effects than zoledronic acid.